

SYNTHESIS AND BIOLOGICAL ACTIVITY OF SOME NEW 1,2,4-TRIAZINO[6,1-B]QUINAZOLINE DERIVATIVES.

BY

Mervat M. El-Enany, Afaf K. El-Ansary, Mona M. Abdel-Gawad and Ehab M. Gedawy.

FROM

Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.

ABSTRACT

In this study, novel 3-substituted 1,2,4-triazino[6,1-b]quinazolines 4a-e, 8-substituted-1H-[1,2,4]triazino[6,1-b]quinazoline-2,4,10(3H)-triones 8a&b and 2-substituted 1,2,4-triazino[6,1-b]quinazolines 9a-d, 10 & 11 were synthesized from 3-amino-6-bromo-2-ethoxycarbonylquinazolin-4(3H)-one (**2b**) and 3-amino-2-aminocarbonylquinazolin-4(3H)-one 7a&b. Some of the newly synthesized compounds were tested for their antimicrobial activity and analgesic activity.

Depending on the obtained results, the newly synthesized compounds possess significant analgesic activity and mild antimicrobial activity.

Introduction

Quinazoline derivatives have been reported to possess diverse biological activities such as analgesic (Alafeefy et al., 2010), anti-inflammatory (Alagarsamy et al., 2007; Chandrika et al., 2008; Giri et al., 2009), antimicrobial (Minu et al., 2008; Panneerselvam et al., 2009; Ryu et al., 2012) and anticancer (Noolvi et al., 2011 and Mulakayala et al., 2012). In addition 1,2,4-triazine derivatives were found to possess antimicrobial activity (Taha M.A.M., 2007 and Elsilk et al., 2010), antitumor activity (Gucky' et al., 2010). Finally, condensed [1,2,4]triazinoquinazoline were reported to have antibacterial and antifungal activity (Abdel-Mageed et al., 1988; Abdel-Hamide et al., 1997; Abdel-Hamide, 2001; Ghorab et al. 2013), anti-inflammatory activity (Bansal et al., 2001 and Hussein, 2012), anticancer activity (Kovalenko et al. 2013) and analgesic activity (Pathak et al. 1995).

The above findings directed the attention to the synthesis of certain substituted [1,2,4]triazino[6,1-b]quinazoline hoping that they may possess antimicrobial activity and analgesic activity.

Discussion

2-amino-5-bromobenzoic acid hydrazide (1b) was prepared from reacting methyl 5-bromoanthranilic acid with hydrazine hydrate adopting Casgranda's precautions (Casgrande et al. 1965). Meanwhile synthesis of 3-Amino-2-ethoxycarbonylquinazolin-4(3H)-one (2a) was prepared via heating 2-aminobenzoic acid hydrazide (1a) with excess diethyl oxalate according to the reported method (George et al. 1971). Finally, 3-Amino-2-aminocarbonylquinazolin-4(3H)-one (7a) was prepared via aminolysis of corresponding amino ester 2a adopting George's conditions (George et al. 1971).

In this study, Certain 3-substituted 1,2,4-triazino[6,1-b]quinazolines 4a-g were synthesized from reacting 3-Amino-6-bromo-2-ethoxycarbonylquinazolin-4(3H)-one (2b) with triethyl orthoformate to afford 6-Bromo-2-ethoxycarbonyl-3-ethoxymethylenaminoquinazolin-4(3H)-one (3). The latter was cyclized with different aliphatic or aromatic amines to afford 4a-g. Meanwhile, reaction of 2b with phenyl isocyanate and formamide yielded 5 & 6 respectively. In addition, 8-Substituted-1H-[1,2,4]triazino[6,1-b]quinazolin-2,4,10(3H)-triones 8a&b were prepared via fusion 3-amino-2-aminocarbonylquinazolin-4(3H)-one 7a&b with urea. Finally, 2-substituted 1,2,4-triazino[6,1-b]quinazolines 9a-d, 10 & 11 from reacting 7a&b with different substituted aromatic aldehydes, chloroacetyl chloride or trifluoroacetic anhydride.

Experimental

Melting points were determined on a Griffin apparatus and are uncorrected.

Microanalysis for C, H and N were carried out at Microanalytical Centre, Cairo University and Organic Microanalyses Section, National Research Centre. IR spectra were recorded on Shimadzu 435 spectrometer using KBr discs. ¹H NMR spectra were performed on a Varian Gemini 200 MHz, Microanalytical Centre, Cairo University using TMS as an internal standard and chemical shift values are recorded in ppm on δ scale. Mass spectra were run at 70 eV on HP-5988A Mass spectrometer. Progress of the reactions was monitored by TLC using aluminium sheets percoated with UV fluorescent silica gel (Merck 60 F254) and were visualized using UV lamp and iodine vapour. The used solvent system was chloroform : benzene : methanol [6: 3.5 : 0.5].

3-Amino-6-bromo-2-ethoxycarbonylquinazolin-4(3H)-one (2b).

A mixture of 2-amino-5-bromobenzoic acid hydrazide 1b (15.18 g, 0.066mol) in diethyl oxalate (19.5mL) was heated under reflux with stirring in an oil bath at 180 °C for 6 h. The excess diethyl oxalate was distilled off under vacuum to give a semisolid mass which upon treatment with ethanol afforded white crystalline solid & finally crystallized from DMF.

Yield: 60.0%; mp: 165-167 °C; IR(cm^{-1}): 3330,3270 (NH), 2975 (C-H aliphatic), 1738, 1680 (C=O); ¹H NMR (DMSO- d_6): 1.4 (t, 3H, CH₃), 4.4 (q, 2H, CH₂), 5.95 (br. s., 2H, NH₂, D₂O exchangeable), 7.6-8.3 (m, 3H, Ar-H); MS: m/z 314 (M+3⁺, 6.86 %), 313 (M+2⁺, 38.82 %), 312 (M+1⁺, 7.27 %), 311 (M⁺, 44.18 %), 74.95 (100%); Anal. for C₁₁H₁₀BrN₃O₃ Calcd. (Found): C, 42.32(42.35); H, 3.23(3.69); N, 13.46(13.72).

6-Bromo-2-ethoxycarbonyl-3-ethoxymethylenaminoquinazolin-4(3H)-one (3)

A solution of 3-amino-6-bromo-2-ethoxycarbonylquinazolin-4(3H)-one (2b) (3.12g, 0.01mol) in triethyl orthoformate (20mL) was heated under reflux for 1.5 h. The excess triethyl orthoformate as well as the formed ethanol were evaporated under reduced pressure. The residue was crystallized from petroleum ether to afford solid.

Yield: 84.0%; mp: 80-82 °C; IR(cm^{-1}): 2960 (C-H aliphatic), 1740, 1680 (C=O); ¹H NMR (DMSO- d_6): 1.4 (t, 6H, 2 CH₃), 4.3-4.4 (q, 2H, CH₂), 4.41-4.5 (q, 2H, CH₂), 7.2-7.8 (m, 3H, Ar-H), 8.6 (s, 1H, -CH=N); Anal. for C₁₄H₁₄BrN₃O₄ Calcd. (Found): C, 45.67(46.20); H, 3.85(4.37); N, 11.41(11.48).

General procedure for the synthesis of 4a-e:

To a solution of 6-Bromo-2-ethoxycarbonyl-3-ethoxymethyl-enaminoquinazolin-4(3H)-one (3) (4.05 g, 0.011mol) in toluene (50mL), the appropriate amine (0.01mol) was added. The reaction mixture was heated on water bath at 50 °C for 10 min. (in case of aliphatic amines), or heated under reflux for 1.5 h. (in case of aromatic amines). The reaction mixture was then cooled, filtered off. The produced solid was washed with chloroform then crystallized from the appropriate solvent to afford 4a-e.

8-Bromo-3-(4-methoxyphenyl)-3H-[1,2,4]triazino[6,1-b]quinazoline-4,10-dione (4a)

Yield: 73.0% (acetic acid); mp: > 300 °C; IR (cm⁻¹); 2970 (C-H aliphatic), 1720, 1680 (2C=O); MS: m/z 401 (M+3⁺, 19.50%), 400 (M+2⁺, 100%), 399 (M+1⁺, 23.17%), 398 (M⁺, 95.50%); Anal. for C₁₇H₁₁BrN₄O₃ Calcd. (Found): C, 51.14(50.91); H, 2.77(2.50); N, 14.03(14.22).

8-Bromo-3-methyl-3H-[1,2,4]triazino[6,1-b]quinazoline-4,10-dione (4b)

Yield: 70.0% (acetic acid); mp: > 300 °C; IR (cm⁻¹); 2970 (C-H aliphatic), 1710, 1670 (2 C=O); Anal. for C₁₁H₇BrN₄O₂ Calcd. (Found): C, 43.02(42.80); H, 2.29(2.10); N, 18.24(18.14).

8-Bromo-3-isopropyl-3H-[1,2,4]triazino[6,1-b]quinazoline-4,10-dione (4c)

Yield: 95.0% (toulene); mp: > 300 °C; IR (cm⁻¹); 2970 (C-H aliphatic), 1710, 1650 (2 C=O); ¹H NMR (DMSO-d₆): 0.93 (d, 6H, 2 CH₃), 2.07-2.11 (m, 1H, CH), 7.8-8.3 (m, 4H, Ar-H + -N=CH); Anal. for C₁₃H₁₁BrN₄O₂ Calcd. (Found): C, 46.56(46.21); H, 3.28(3.29); N, 16.71(16.69).

8-Bromo-3-isobutyl-3H-[1,2,4]triazino[6,1-b]quinazoline -4,10-dione (4d)

Yield: 95.0% (toulene); mp: > 300 °C; IR (cm⁻¹); 2970 (C-H aliphatic), 1720, 1650 (2 C=O); MS: m/z 351 (M+3⁺, 13.35 %), 350 (M+2⁺, 78.2 %), 349 (M+1⁺, 15.93 %), 348 (M⁺, 77.20 %), 294.90 (100 %) ; Anal. for C₁₄H₁₃BrN₄O₂ Calcd. (Found): C, 48.13(48.68); H, 3.72(3.84); N, 16.04(16.05).

8-Bromo-3-cyclohexyl-3H-[1,2,4]triazino[6,1-b]quinazoline-4,10-dione (4e)

Yield: 95.0% (CHCl₄/methanol); mp: > 300 °C; IR (cm⁻¹); 2970 (C-H aliphatic), 1710, 1660 (2C=O); ¹H NMR (DMSO-d₆): 1.20-1.88 (m, 10H, C-H of 5 CH₂), 4.45 (m, 1 H, CH cyclohexyl), 7.80-8.11 (m, 4H, Ar-H + -N=CH); Anal. for C₁₆H₁₅BrN₄O₂ Calcd. (Found): C, 51.21(51.80); H, 4.02(4.41); N, 14.93(14.77).

methyl 2-(8-bromo-4,10-dioxo-4,10-dihydro-3H-[1,2,4]triazino[6,1-b] quinazolin-3-yl)benzoate (4f)

Yield: 75.0% (pet. ether); mp: 180-182 °C; IR (cm⁻¹); 2970 (C-H aliphatic), 1700, 1660 (2 C=O); MS: m/z 429 (M+3⁺, 13.41 %), 428 (M+2⁺, 56.26 %), 427 (M+1⁺, 14.44 %), 426 (M⁺, 56.26 %), 369 (100 %) ; Anal. for C₁₈H₁₁BrN₄O₄ Calcd. (Found): C, 50.60(50.54); H, 2.59(2.45); N, 13.11(13.08).

3-Amino-8-Bromo-3H-[1,2,4]triazino[6,1-b]quinazoline-4,10-dione (4g)

Yield: 70.0% (acetic acid); mp: 296-298 °C; IR (cm⁻¹); 3210-3200 (NH₂), 2970 (C-H aliphatic), 1710, 1670 (2 C=O); Anal. for C₁₀H₆BrN₅O₂ Calcd. (Found): C, 38.98(39.20); H, 1.96(2.20); N, 22.73(22.56).

General procedure for the synthesis of 5 a&b:

Phenyl iso(thio)cyanate (0.006mol) was added to a solution of 6-Bromo-2-ethoxycarbonyl-3-ethoxymethyl-enaminoquinazolin-4(3H)-one (3) (1.56g, 0.005 mol) in glacial acetic acid (15mL). The reaction mixture was heated under reflux for 6h., then allowed to cool. The separated yellow precipitate was filtered off and crystallized from acetic acid to yield 5 a&b.

8-Bromo-3-phenyl-1H-[1,2,4]triazino[6,1-b]quinazoline-2,4,10(3H)-trione (5a)

Yield: 85.0%; mp: > 300 °C; IR (cm⁻¹); 3150 (NH), 1740, 1680, 1640 (3 C=O); MS: m/z 386 (M+2⁺, 26.47 %), 384 (M⁺, 25.52 %), 119 (100 %); Anal. for C₁₆H₉BrN₄O₃ Calcd. (Found): C, 49.89(49.58); H, 2.35(2.50); N, 14.54(14.50).

8-Bromo-3-phenyl-2-thioxo-1H-[1,2,4]triazino[6,1-b]quinazoline-4,10(3H)-dione (5b)

Yield: 80.0%; mp: > 300 °C; IR (cm⁻¹); 3250 (NH), 1680-1650 (2 overlapped C=O); Anal. for C₁₆H₉BrN₄O₂S Calcd. (Found): C, 47.90(47.85); H, 2.26(2.64); N, 13.96(13.83).

8-Bromo-3H-[1,2,4]triazino[6,1-b]quinazoline-4,10-dione (6)

A solution of 6-Bromo-2-ethoxycarbonyl-3-ethoxymethyl-enaminoquinazolin-4(3H)-one (3) (3.12g, 0.01mol) in formamide was heated under reflux for 40-50 min., then allowed to cool to room temperature. The separated white precipitate was collected by filtration and crystallized from acetic acid.

Yield: 65.0% (pet. ether); mp: > 300 °C; IR (cm⁻¹); 3300-3100 (NH), 1690-1680 (2overlapped C=O); MS: m/z 293 (M+1⁺, 26.47%), 291 (M-1⁺, 2.17%), 264 (100%); Anal. for C₁₀H₅BrN₄O₂ Calcd. (Found): C, 40.98(41.10); H, 1.71(1.75); N, 19.11(18.97).

3-Amino-2-aminocarbonyl-6-bromoquinazolin-4(3H)-one (7b)

A mixture of 3-Amino-6-bromo-2-ethoxycarbonylquinazolin-4(3H)-one (2b), aqueous ammonium hydroxide solution 33 % (15mL) and ethanol (10mL) was heated under reflux for 2h. with continuous stirring. The reaction mixture was then cooled, filtered off and the product was crystallized from ethanol.

Yield: 65.0%; mp: 185-187 °C; IR (cm⁻¹); 3300, 3200 (NH₂), 1680, 1630 (2 C=O); MS: m/z 283.9 (M+2⁺, 20.38%), 281.9 (M⁺, 20.53%), 209.95 (100%); Anal. for C₉H₇BrN₄O₂ Calcd. (Found): C, 38.16(38.50); H, 2.47(2.70); N, 19.78 (19.70).

8-Substituted-1H-[1,2,4]triazino[6,1-b]quinazoline-2,4,10(3H)-triones 8a&b

A solution of the respective 3-amino-2-aminocarbonylquinazolin-4(3H)-one 7a&b (0.02 mol) and finely grinded urea (3.6g, 0.06mol) was fused in an oil bath at 190 °C for 2 h. the crude product was washed with hot water (30 mL), dissolved in NaOH 10% (100mL), treated with charcoal, filtered off and precipitated by acetic acid. The formed yellow solid was filtered, washed with water and recrystallized from glacial acetic acid to yield 7a&b.

1H-[1,2,4]triazino[6,1-b]quinazoline-2,4,10(3H)-triones (8a)

Yield: 75.0%; mp: > 300 °C; IR (cm⁻¹); 3500-3200 (NH), 1700, 1660, 1650 (3C=O); MS: m/z 231 (M+1⁺, 15.93%), 230 (M⁺, 87.91%), 103 (100%); Anal. for C₁₀H₆N₄O₃ Calcd. (Found): C, 52.18 (51.66); H, 2.62(2.65); N, 24.33 (24.42).

8-Bromo-1H-[1,2,4]triazino[6,1-b]quinazoline-2,4,10(3H)-triones (8b)

Yield: 80.0%; mp: > 300 °C; IR (cm⁻¹); 3500-3200 (NH), 1700, 1660, 1650 (3C=O); ¹H NMR (DMSO-d₆): 5.5 (s, 1H, N¹H, D₂O exchangeable), 7.80-8.40 (m, 3H, Ar-H), 12.20 (s, 1H, N³H, D₂O exchangeable); Anal. for C₁₀H₅BrN₄O₃ Calcd. (Found): C, 38.86(39.00); H, 1.63(1.59); N, 18.12(18.06).

2-Aryl-8-substituted-3H-[1,2,4]triazino[6,1-b]quinazoline-4,10(3H)-diones (9a-d)

A mixture of the respective 3-amino-2-aminocarbonylquinazolin-4(3H)-ones 7a&b and appropriate aromatic aldehyde (0.01mol) in dry dimethylformamide (25 mL) containing hydrochloric acid (0.2mL) was heated under reflux for 24 h. After cooling, the reaction mixture was poured into ice-cold water (25mL). The separated yellow solid was filtered off and crystallized from glacial acetic acid.

2-(4-Chlorophenyl)- 3H-[1,2,4]triazino[6,1-b]quinazoline-4,10(3H)-dione (9a)

Yield: 75.0%; mp: > 300 °C; IR (cm⁻¹); 3300-3100 (NH), 1720, 1690 (2 C=O); ¹H NMR (DMSO-d₆): 7.60-8.30 (m, 8H, Ar-H), 12.40 (s, 1H, N³H, D₂O exchangeable); Anal. for C₁₆H₉ClN₄O₂ Calcd. (Found): C, 59.18 (59.20); H, 2.79 (2.90); N, 17.25(17.21).

2-(2-Bromophenyl)- 3H-[1,2,4]triazino[6,1-b]quinazoline-4,10(3H)-dione (9b)

Yield: 70.0%; mp: > 300 °C; IR (cm⁻¹); 3300-3100 (NH), 1700, 1680 (2 C=O); MS: m/z 370 (M+2⁺, 0.09%), 368 (M⁺, 0.2%), 228 (100%); Anal. for C₁₆H₉BrN₄O₂ Calcd. (Found): C, 52.05(51.98); H, 2.45(2.64); N, 15.17(15.52).

8-Bromo-2-(4-nitrophenyl)-3H-[1,2,4]triazino[6,1-b]quinazoline-4,10(3H)-dione (9c)

Yield: 65.0%; mp: 252-254 °C; IR (cm⁻¹); 3300-3100 (NH), 1700, 1660 (2C=O); Anal. for C₁₆H₈BrN₅O₄ Calcd. (Found): C, 46.39(46.33); H, 1.94(2.39); N, 16.90(16.83).

2-(2-nitrophenyl)-3H-[1,2,4]triazino[6,1-b]quinazoline-4,10(3H)-dione (9d)

Yield: 60.0%; mp: 272-274 °C; IR (cm⁻¹); 3300-3200 (NH), 1700, 1660 (2 C=O); Anal. for C₁₆H₉N₅O₄ Calcd. (Found): C, 57.31(57.49); H, 2.70(3.11); N, 20.88(20.53).

2-(Trifluoromethyl)-3H-[1,2,4]triazino[6,1-b]quinazoline-4,10-dione (10)

A suspension of 3-amino-2-aminocarbonylquinazolin-4(3H)-one (7a) (2.04 gm, 0.01mol) in trifluoroacetic acid (15mL) was heated under reflux on a water bath at temperature 38 °C for 24h. After cooling, the reaction mixture was poured portionwise carefully onto crushed ice (30 g). The formed white precipitate was filtered off and crystallized from glacial acetic acid.

Yield: 60.0%; mp: > 300 °C; IR (cm⁻¹); 3200 (NH), 1720, 1660 (2 C=O); MS: m/z 281 (M-1⁺, 2.71%), 119 (100%); Anal. for C₁₁H₅F₃N₄O₂ Calcd.(Found): C, 46.82(46.70); H, 1.78(1.90); N, 19.85(20.00).

2-(Chloromethyl)-3H-[1,2,4]triazino[6,1-b]quinazoline-4,10-dione (11)

Chloroacetyl chloride (1.13mL, 0.01mol) was added dropwise to a suspension of 3-amino-2-aminocarbonylquinazolin-4(3H)-one (7a) (2,3g, 0.01mol) in acetic acid (50mL). The reaction mixture was heated under reflux for 6h. and then allowed to cool in an ice bath. The separated solid was filtered off and crystallized from ethanol.

Yield: 61.0%; mp: > 300 °C; IR (cm⁻¹); 3300-3100 (NH), 2960 (C-H aliphatic) 1720 ,1660 (2 C=O); MS: m/z 264 (M+2⁺, 35.33%), 263 (M+1⁺, 15.8%),262 (M⁺, 100%); Anal. for C₁₁H₇ClN₄O₂ Calcd. (Found): C, 50.30 (49.98); H, 2.68 (2.91); N, 21.33 (21.12).

Antimicrobial activity testing:

Six of the newly synthesized compounds were evaluated for their in-vitro antimicrobial activity against Staphylococcus aureus (Gram-positive), Bacillus subtilis (Gram-positive), Escherichia coli (Gram-negative), Pseudomonas aeruginosa (Gram-negative) and Candida albicans (Fungi).

Methodology

Using the agar plate disc-diffusion methodology (); agar plates containing 15 mL of agar medium were seeded with 0.2 mL of 18 hours broth culture of each organism.

Sterile filter paper discs (6 mm in diameter) were impregnated each with 10 µL of a saturated solution of the tested compounds in DMF and allowed to air drying. The discs were then placed onto the surface of agar plates and incubated at 37 °C for 48 hours.

Control discs impregnated with DMF were used to determine the solvent activity. The diameter of the inhibition zone around each disc was measured in mm.

The bacterial ciprofloxacin reference disc was tested as standard.

Conclusion

The obtained data (table 1) revealed that compounds 4b & 5b showed mild antibacterial activity against Gram-negative while compounds 8b & 9d showed mild antibacterial activity against Gram- positive, meanwhile compound 4b showed also mild antifungal activity.

Analgesic activity testing

Two compounds were tested for their analgesic activity via “ acetic acid Induced Writhing Test” using aspirin as standard.

Methodology:**1- Animals:**

Adult albino Swiss-Webster mic (18-25 g) of both sex, the animals were divided into four groups each of ten animals. They were housed in a quiet, temperature and humidity-controlled room (22 ± 3 °C and 60 ± 5 % respectively).

2- Drug administration:

The synthesized compounds (15 mg/Kg) and the tested used reference analgesic , aspirin (15 mg/Kg) were suspended in tween 80 and injected intraperitoneally.

3- Acetic Acid Induced Writhing Test():

The animals react with characteristic stretching behavior which is called wriyhing, when ininjected with an irritant such as acetic acid (0.6 %. 10 mL/Kg) into the peritoneal cavity of the mice.

The first two animal groups were administered the tested compounds in dose (15 mg/Kg) intraperitoneally followed by the intraperitoneal injection of acetic acid 30 min. later. The third group was dosed with the standard reference drug (aspirin) in the same dose of the tested compounds 30 min. before the injection of theacetic acid. Finally the fourth group was injected with tween 80 only as a test control.

The tested mice were observed for the total number of writhines within 20 min. after the acetic acid injection.


The mean values of each group and the percent of reduction of the writhes number were also calculated with respect to these of the control group.

Conclusion:

The tested compounds 4g & 9c were found to decrease the number of writhes induced by the injected acetic acid.

The analgesic activity of the two tested compounds were shown to be more potent than the analgesic activity of asirin.

Scheme 1:




Scheme 2:

Table 1: Antimicrobial activity of newly synthesized compounds on different microorganisms.

Compound no.	Diameter of zone of inhibition in mm				
	In vitro activity against				
	S. aureus	B. subtilis	E. coli	P. aeruginosa	C. albicans
4b	-	-	5	-	5.5
5b	-	-	-	5	-
8b	6	-	-	-	-
9d	6	-	-	-	-
10	-	-	-	-	-
11	-	-	-	-	-
DMF	-	-	-	-	-
Ciprofloxacin	9	10	10	11	-

Table 2: Analgesic activity of newly synthesized compounds

Compound no.	Mean of the no. of writhes within 20 min. (x)	Standard Error (SE)	% Reduction from the control $(x-c/c) \times 100$
4g	1.667	0.527	62.95
9c	0.80	0.132	82.20
Aspirin	2.1	0.314	53.33
Control	4.5	0.289	-

REFERENCES

- Abdel-Hamide S.G.,(1997): J. Ind. Chem. Soc., 74, 613.
- Abdel-Hamide S.G.,(2001): Saudi Pharmaceutical Journal, 9(2), 72.
- Abdel-Mageed, M.F., Teniou, A., (1988): Collect. Czech. Chim. Commun., 53(2), 329.
- Alafeefy A.M., Kadi A.A., Al-Deeb O.A., El-Tahir K.E., Al-Jaber N.A., (2010): Eur. J. Med. Chem., 11, 4947.
- Alagarsamy V., Solomon V.R., Dhanabal K., (2007); Bioorg. Med. Chem., 15, 235.
- Bansal E., Ram T., Sharma, S., Tyagi M., Rani A.P., Bajaj K., Taygi R., Goel B., Srivastava V.K., Guru, J.N., Kumar, A., (2001): Ind. J., Chem., 40B(4), 307.

- Chandrika P. M., Yakaiah T., Rao A.R.R., Narsaiah B., Reddy N. C., Sridhar V., Rao J.V., (2008):** *Eur. J. Med. Chem.*, 43, 846.
- Casgrande, C., Canova M., Ferrari G., (1965):** *Farmaco*, 20(8), 544.
- Elsilk S.E., El-barbary A.A., 2010:** *Middle-East J. of Sci. res.* 6(1), 31.
- George T., Mehta D.V., Tahilramani R., (1971):** *Ind. J., Chem.*, 9, 755.
- Giri R.S., Thaker H.M., Giordano T., Williams J., Rogers D., Sudersanam V., Vasu K. K., (2009):** *Eur. J. Med. Chem.*, 44, 2184.
- Ghorab M.M., Ismail Z.H., Abdalla M., Radwan A.A., (2013):** *Arch. Pharm. Res.*, 36, 660.
- Gucky´ T., Reznickova E., Dzubak P., Hajduch M., Krystof V., (2010):** *Monatsh Chem.*, 141, 709.
- Hussein M.A., (2012):** *Med Chem Res*, 21, 1876.
- Kovalenko S.I., Nosulenko I.S., Voskoboynik A.Y., Berest G.G., Antipenko L.N., Antipenko A.N., Katsev A.M., (2013):** *Med. Chem. Res.*, 22, 2610.
- Minu M., Thangadurai A., Wakode S.R., Agrawal S.S., Narasimhan B., (2008):** *Arch. Pharm. Chem. Life Sci.*, 341, 231.
- Mulakayala N., Kandagatla B., Ismail, Rapolu R.K., Rao P., Mulakayala C., Kumar C.S., Iqbal J., Oruganti S., (2012):** *Bioorg. Med. Chem. Letters*, 22, 5063.
- Noolvi M.N., Patel H.M., Bhardwaj V., Chauhan A., (2011):** *Eur. J. Med. Chem.*, 46, 2327.
- Panneerselvam P., Rather B.A., Reddy D.R.S., Kumar N.R., (2009):** *Eur. J. Med. Chem.*, 44, 2328.
- Pathak, U.S., Rathod I.S., Patel M.B., Shirsath V.S., Jain K.S., (1995):** *Ind. J., Chem.*, 44B, 617.
- Ryu C.K., Kim Y.H., Im H.A., J.Y. Kim, Yoon J.H., Kim A., (2012):** *Bioorg. Med. Chem.*, 22, 500.
- Taha M.A.M., (2007):** *Monatshefte fur Chemie* 138, 505.

الملخص العربي

تشبيد بعض مركبات ترايزينوكينازولين جديدة ذات تأثير بيولوجي متوقع

للسادة الدكتورة

مرفت مصطفى العناني، عفاف كمال الدين الانصاري، منى محمد عبد الجواد، ايهاب محمد عبدالمنعم جداري

من

قسم الكيمياء العضوية الصيدلانية - كلية الصيدلة - جامعة القاهرة - مصر

في هذا البحث تم تشبيد مشتقات (١,٢,٤)-ترايزينو[٦,١-ب]كينازولين ٤، ٨، ٩، ١٠، ١١ من ٢-امينو-٦-برومو-٢-ايثوكسي كربونيل كينازولين ٤-(٣يد-ون (٤ب) و ٣-امينو-٢-امينوكاربونيل كينازولين ٤-(٣يد-ون (٧أ،ب). تم اختبار بعض المركبات المحضرة حديثا لنشاطهم مضادات الميكروبات والنشاط مسكن . اعتمادا على النتائج التي تم التوصل اليها ، و المركبات المشييدة حديثا تمتلك نشاط كبير مسكن والنشاط المضادة للميكروبات خفيفة